Overharvesting has raised conservation concerns for a widely foraged plant, but researchers say that better genetic insights ...

Colorectal cancer breaks the usual immune rules, with certain regulatory T cells linked to improved survival. In many solid ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

The widespread use of microsatellite markers in genome-wide association (GWA) studies, as supported by Bahram and Inoko, currently faces several obstacles. These include determining genome-wide ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translational findings supporting ...

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

Parks Associates, a leading research and consulting authority on connected lifestyle technologies and technology solutions for business, today released its 2025 Top Leaders in Technology, an annual ...

A new study from Memorial Sloan Kettering Cancer Center finds that in colorectal cancer, not all regulatory T cells are created equal. One subtype suppresses cancer growth while another aids it. The ...

Pelareorep (Reolysin), an intravenously delivered oncolytic virus immunotherapy, has demonstrated positive second-line ...

As of Tuesday, December 23, Burning Rock Biotech Limited’s BNR share price has dipped by 9.53%, which has investors questioning if this is right time to buy.